Wang W, Erbe AK, Gallenberger M, Kim KM, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng S-C, Signoretti S, Atkins M, Carlson A, Weiss JM, Mier J, Panka D, McDermott DF, Sondel PM. Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunol Immunother. 2016 Dec;65(12):1523-1532. - Stand Up To Cancer

Blog

Posted September 23, 2019

Wang W, Erbe AK, Gallenberger M, Kim KM, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng S-C, Signoretti S, Atkins M, Carlson A, Weiss JM, Mier J, Panka D, McDermott DF, Sondel PM. Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunol Immunother. 2016 Dec;65(12):1523-1532.

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.